OBJECTIVE: The purpose of this study was to investigate the relation between angiographic embolic endpoints of transarterial chemoembolization (TACE) and the survival of patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This study was a retrospective assessment of the cases of 105 patients with surgically unresectable HCC who underwent TACE. The cases were classified according to a previously established subjective angiographic chemoembolization endpoint scale. Only one patient had endpoint level I embolization and was excluded from all subsequent analysis. Survival was evaluated with Kaplan-Meier analysis. The Cox proportional hazards model was used to determine independent prognostic risk factors of survival. RESULTS: The overall median survival period was 21.1 months (95% CI, 15.9-26.4 months). Patients with embolization to subjective angiographic chemoembolization endpoint levels II and III were aggregated and had a significantly longer median survival period (25.6 months; 95% CI, 16.2-35.0 months) than patients with embolization to level IV (17.1 months; 95% CI, 13.3-20.9 months) (p = 0.035). The results of multivariate analysis indicated that all of the following factors were independent negative prognostic indicators of survival: subjective angiographic chemoembolization endpoint level IV (hazard ratio [HR], 2.49; 95% CI, 1.41-4.42; p = 0.002), European Cooperative Oncology Group performance status greater than 0 (HR, 1.97; 95% CI, 1.15-3.37; p = 0.013), American Joint Committee on Cancer stage III or IV (HR, 2.42; 95% CI, 1.27-4.60; p = 0.007), and Child-Pugh class B (HR, 1.94; 95% CI, 1.09-3.46; p = 0.025). CONCLUSION: Embolization to an intermediate, substasis endpoint (subjective angiographic chemoembolization endpoint levels II and III) during TACE improves survival compared with embolization to a higher, stasis endpoint (level IV). Interventional oncologists should consider aiming for these intermediate, substasis angiographic endpoints during TACE.
OBJECTIVE: The purpose of this study was to investigate the relation between angiographic embolic endpoints of transarterial chemoembolization (TACE) and the survival of patients with hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This study was a retrospective assessment of the cases of 105 patients with surgically unresectable HCC who underwent TACE. The cases were classified according to a previously established subjective angiographic chemoembolization endpoint scale. Only one patient had endpoint level I embolization and was excluded from all subsequent analysis. Survival was evaluated with Kaplan-Meier analysis. The Cox proportional hazards model was used to determine independent prognostic risk factors of survival. RESULTS: The overall median survival period was 21.1 months (95% CI, 15.9-26.4 months). Patients with embolization to subjective angiographic chemoembolization endpoint levels II and III were aggregated and had a significantly longer median survival period (25.6 months; 95% CI, 16.2-35.0 months) than patients with embolization to level IV (17.1 months; 95% CI, 13.3-20.9 months) (p = 0.035). The results of multivariate analysis indicated that all of the following factors were independent negative prognostic indicators of survival: subjective angiographic chemoembolization endpoint level IV (hazard ratio [HR], 2.49; 95% CI, 1.41-4.42; p = 0.002), European Cooperative Oncology Group performance status greater than 0 (HR, 1.97; 95% CI, 1.15-3.37; p = 0.013), American Joint Committee on Cancer stage III or IV (HR, 2.42; 95% CI, 1.27-4.60; p = 0.007), and Child-Pugh class B (HR, 1.94; 95% CI, 1.09-3.46; p = 0.025). CONCLUSION: Embolization to an intermediate, substasis endpoint (subjective angiographic chemoembolization endpoint levels II and III) during TACE improves survival compared with embolization to a higher, stasis endpoint (level IV). Interventional oncologists should consider aiming for these intermediate, substasis angiographic endpoints during TACE.
Authors: Jean-Francois H Geschwind; Douglas E Ramsey; Berry Cleffken; B C H van der Wal; Hicham Kobeiter; Krishna Juluru; George G Hartnell; Michael A Choti Journal: Cardiovasc Intervent Radiol Date: 2003-03-06 Impact factor: 2.740
Authors: Michael J Wallace; Ravi Murthy; Paresh P Kamat; Teri Moore; Sujaya H Rao; Joe Ensor; Sanjay Gupta; Kamran Ahrar; David C Madoff; Stephen E McRae; Marshall E Hicks Journal: J Vasc Interv Radiol Date: 2007-12 Impact factor: 3.464
Authors: Daniel B Brown; Jean-Francois H Geschwind; Michael C Soulen; Steven F Millward; David Sacks Journal: J Vasc Interv Radiol Date: 2009-07 Impact factor: 3.464
Authors: Dingxin Wang; Brian Jin; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Mary F Mulcahy; Laura M Kulik; Frank H Miller; Riad Salem; Debiao Li; Reed A Omary; Andrew C Larson Journal: J Magn Reson Imaging Date: 2010-05 Impact factor: 4.813
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail Journal: Future Oncol Date: 2018-06-26 Impact factor: 3.404
Authors: Dingxin Wang; Ron C Gaba; Brian Jin; Robert J Lewandowski; Ahsun Riaz; Khairuddin Memon; Robert K Ryu; Kent T Sato; Laura M Kulik; Mary F Mulcahy; Andrew C Larson; Riad Salem; Reed A Omary Journal: Radiology Date: 2014-03-28 Impact factor: 11.105
Authors: Ali Pirasteh; E Aleks Sorra; Hector Marquez; Robert C Sibley; Julia R Fielding; Abhinav Vij; Nicole E Rich; Ana Arroyo; Adam C Yopp; Gaurav Khatri; Amit G Singal; Takeshi Yokoo Journal: Abdom Radiol (NY) Date: 2021-03-23
Authors: F Edward Boas; Nancy E Kemeny; Constantinos T Sofocleous; Randy Yeh; Vanessa R Thompson; Meier Hsu; Chaya S Moskowitz; Etay Ziv; Hooman Yarmohammadi; Achiude Bendet; Stephen B Solomon Journal: Radiology Date: 2021-08-31 Impact factor: 11.105
Authors: Rebecca M Dodson; Amin Firoozmand; Omar Hyder; Vania Tacher; David P Cosgrove; Nikhil Bhagat; Joseph M Herman; Christopher L Wolfgang; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2013-09-25 Impact factor: 3.452